Mesh Regular Surgical Meshe Articles & Analysis
7 news found
The University of Chicago Medicine has announced today that it is now enrolling patients into LymphBridge, a randomized clinical study to evaluate a novel investigational surgical device for the treatment of breast cancer-related lymphedema. This study is sponsored by Fibralign Corporation with funding provided by the National Cancer Institute (NCI) and being led by world-renowned microsurgeon ...
Fibralign Corp., a Stanford spin-out and developer of therapeutic biomedical devices, today announced enrollment of the first patient in a multi-site, randomized clinical trial in Europe evaluating its BioBridge® Collagen Matrix as a novel preventative treatment for secondary lymphedema. The study plans to enroll 40 patients that have been diagnosed with advanced stage breast cancer and ...
Fibralign Corp., a Stanford spin-out and developer of therapeutic biomedical devices, today announced that it has received CE mark for its first product, the BioBridge Collagen Matrix. BioBridge is classified as a Class III device with an indication for use to support lymphatic tissue repair and can be used after or in conjunction with surgical procedures addressing lymphedema. CE mark is a ...
Fibralign Corp., a Stanford spin-out developer of therapeutic biomedical devices, has announced today that it has executed a long term distributor agreement with Terumo Corporation to market and distribute the BioBridge® Collagen Matrix in Japan for treating and preventing secondary lymphedema. BioBridge is a sterile implantable biocompatible and biodegradable surgical mesh made of highly ...
Silver Bullet Therapeutics, Inc., a privately-held medical device company committed to the development of antimicrobial medical devices, announced today that the U.S. Patent and Trademark Office allowed a new patent, BONE IMPLANTS FOR THE TREATMENT OF INFECTION. The company also announced that it has made an expedited CE Mark filing for a significantly expanded OrthoFuzIon Antimicrobial Bone ...
Silver Bullet Therapeutics, Inc., a privately-held medical device company, announced today that the U.S. Patent and Trademark Office allowed two new patents that include, COATINGS FOR THE CONTROLLABLE RELEASE OF ANTIMICROBIAL METAL IONS and BONE IMPLANT AND SYSTEMS THAT CONTROLLABLY RELEASES SILVER. The Company also announced that they will make the OrthoFuzIon Antimicrobial Bone Screw System ...
Silver Bullet Therapeutics, Inc., a privately-held medical device company, announced today that the U.S. Patent and Trademark Office issued Patent No. 8,999,367 as a continuation of patent No. 8,927,004 that significantly enhances the claims for the release of antimicrobial metal ions to prevent infection. Paul Chirico, President and CEO of Silver Bullet Therapeutics stated, “We take a lot ...